Advances in alcoholic liver disease

Area of Science:

• Hepatology
• Gastroenterology
• Internal Medicine

Background:

• Alcoholic liver disease (ALD) is a leading cause of liver-related mortality in the US.
• ALD presents a grave prognosis, exceeding that of many common cancers, with high mortality rates in patients with cirrhosis and alcoholic hepatitis.
• The disease imposes substantial economic burdens due to healthcare costs, lost wages, and reduced productivity.

Purpose of the Study:

• To review recent advances in understanding the mechanisms of liver injury in ALD.
• To explore potential therapeutic strategies targeting key pathways involved in ALD.
• To identify reasons for the limited success of therapies in human clinical trials despite promising preclinical data.

Main Methods:

• Literature review focusing on five major areas relevant to ALD: oxidative stress, gut-liver axis and cytokine signaling, malnutrition, fibrin/clotting, and stellate cell activation/fibrosis.
• Analysis of preclinical (in vitro and animal) studies on therapeutic interventions.
• Evaluation of the translation of these therapies to human clinical trials.

Main Results:

• Significant progress has been made in understanding the molecular mechanisms of ALD, including the roles of oxidative stress, gut dysbiosis, inflammation, and fibrosis.
• Numerous therapeutic approaches targeting these mechanisms have shown efficacy in experimental models.
• A critical gap exists between promising preclinical results and successful clinical outcomes in human patients with ALD.

Conclusions:

• A deeper understanding of ALD pathogenesis is crucial for developing effective treatments.
• Translating findings from experimental systems to human ALD therapy remains a significant challenge.
• Future research should focus on bridging the gap between preclinical efficacy and clinical translation for ALD treatments.